Low concentrations of glucose degradation products in peritoneal dialysis fluids and their impact on biocompatibility parameters: prospective cross-over study with a three-compartment bag.

The side effects of glucose degradation products (GDPs) in conventional peritoneal dialysis (PD) fluids are well described. Using the three-compartment bag concept--that is, in situ preparation of concentrated glucose solution into a standard ionic solution--a GDP-free solution can be processed. To investigate the possible impact of this product on biological and clinical parameters, we carried out a prospective cross-over study with 31 patients, comparing the short-term effects of conventional PD and GDP-free PD solutions.

Long-term influence of dialysis treatment on beta 2-microglobulin, interleukin-2 R and tumour necrosis factor.

Recently much interest has been focused on the phenomena produced by the interaction between blood and dialytic membranes. The aim of this study was to evaluate beta 2-M, Il-2 and TNF changes in relation to the long-term use of different membranes (CU, PAN-AN69, PMMA, PS) and different dialytic treatments (HD, HDF, AFB). Plasma beta 2-M was significantly increased in patients dialysed with CU compared to synthetic membranes, and decreased in AFB compared to HD and HDF.

Muzolimine in patients on chronic hemodialysis (HD) and continuous ambulatory peritoneal dialysis (CAPD).

The importance of the urine volume and the residual functional capacity of the kidneys has been emphasized by several authors in connection with preservation of the quality of life of patients having to undergo chronic dialysis therapy. Since it has been found that muzolimine can increase diuresis even in patients with extremely high uraemia (GFR values less than 5 ml/min), a group of 16 patients (10 haemodialysis patients, HD, and 6 peritoneal dialysis patients, CAPD) was treated daily with 90 mg for a period of one year, commencing with the start of dialysis therapy. The aim of the study was to monitor the diuresis and to evaluate any changes in the quality of life.